Ramucirumab

Name: Ramucirumab C889214
SKU: 08000229_C889214
Price: 182.70 EUR
Availability: InStock

Therapeutic Ramucirumab antibody from the original Cyramza® commercial drug.

Showing all 6 results

Filter our product list:

Product Batch	Antigen	Molecular Class	Drug Brand	Product Concentration	CoA	Quantity per vial	Storage Temperature	Expiry Date	Price from
Ramucirumab C595845	VEGFR2	Monoclonal Antibody	Cyramza®	10 mg/mL	–	2 mg	-80°C	03/2018	182,70 €	view product Max: 10 Min: 2 Step: 1
Ramucirumab C716603	VEGFR2	Monoclonal Antibody	Cyramza®	10 mg/mL	–	2 mg	-80°C	06/2018	182,70 €	view product Max: 10 Min: 2 Step: 1
Ramucirumab C776706	VEGFR2	Monoclonal Antibody	Cyramza®	10 mg/mL	–	2 mg	-80°C	08/2018	182,70 €	view product Max: 10 Min: 2 Step: 1
Ramucirumab C826012	VEGFR2	Monoclonal Antibody	Cyramza®	10 mg/mL	–	2 mg	-80°C	01/2019	182,70 €	view product Max: 10 Min: 2 Step: 1
Ramucirumab C856707	VEGFR2	Monoclonal Antibody	Cyramza®	10 mg/mL	–	2 mg	-80°C	12/2019	182,70 €	view product Max: 10 Min: 2 Step: 1
Ramucirumab C889214	VEGFR2	Monoclonal Antibody	Cyramza®	10 mg/mL	–	2 mg	-80°C	06/2020	182,70 €	view product Max: 8 Min: 2 Step: 1

Not looking for Ramucirumab?

Search our therapeutic molecules product database

Cyramza® / Ramucirumab Reference Product

Drug name	Cyramza®
INN	Ramucirumab
API type	Ramucirumab is a human IgG1 monoclonal antibody produced in murine (NS0) cells by recombinant DNA technology.
Pharmacotherapeutic group	Antineoplastic agents, monoclonal antibodies
ATC code	L01XC21
Target of antibody	VEGFR2; Synonyms: CD309, FLK1, VEGFR, 6130401C07, Flk-1, Flk1, Krd-1, Ly73, VEGFR-2, sVEGFR2, Vegfr-2, FLK-1, flk-1, vegfr-2, KDR, FLK/KDR, flk1, flk1b, kdrb, si:busm1-205d10.1, si:ch211-254j6.1, si:ch211-278f21.4, wu:fc31a09
General function
Short description
Pharmacodynamic properties (Mechanism of action; Source EMA document)	Vascular Endothelial Growth Factor (VEGF) Receptor 2 is the key mediator of VEGF induced angiogenesis. Ramucirumab is a human receptor-targeted antibody that specifically binds VEGF Receptor 2 and blocks binding of VEGF-A, VEGF-C, and VEGF-D. As a result, ramucirumab inhibits ligand stimulated activation of VEGF Receptor 2 and its downstream signalling components, including p44/p42 mitogen-activated protein kinases, neutralising ligand-induced proliferation and migration of human endothelial cells.
Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document)
Original license holder
Marketing authorisation numbers	EU/1/14/957/001 - 003
Marketing authorisation holder	Eli Lilly Nederland B.V. Papendorpseweg 83 3528 BJ Utrecht The Netherlands
Name of the manufacturer of the biological active substance	ImClone Systems LLC 33 ImClone Drive, Branchburg New Jersey NJ 08876 UNITED STATES Eli Lilly S.A. Dunderrow Kinsale County Cork Ireland
Name and address of the manufacturer(s) responsible for batch release	Lilly, S.A. Avda de la Industria, 30 Alcobendas 28108 Madrid Spain
Max shelf life	36 months
Storage conditions	2°C – 8°C
List of excipients	Histidine Histidine monohydrochloride Sodium chloride Glycine (E640) Polysorbate 80 (E433) Water for injections